PT867178E - Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono - Google Patents

Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono

Info

Publication number: PT867178E
Authority: PT; Portugal
Prior art keywords: gaba; sleep disorders; alostericos; agonists; treatment
Prior art date: 1995-07-13

Application number

PT98102355T

Other languages

English (en)

Inventor

Marike Lancel

Original Assignee

Max Planck Ges Zur Forderung W

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-13

Filing date

1996-07-10

Publication date

2002-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT867178(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-10 Application filed by Max Planck Ges Zur Forderung W filed Critical Max Planck Ges Zur Forderung W

2002-04-29 Publication of PT867178E publication Critical patent/PT867178E/pt

Links

239000000556 agonist Substances 0.000 title abstract 2
208000019116 sleep disease Diseases 0.000 title abstract 2
230000003281 allosteric effect Effects 0.000 abstract 1
229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)

PT98102355T 1995-07-13 1996-07-10 Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono PT867178E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19525598A DE19525598C2 (de)	1995-07-13	1995-07-13	Schlafmittel

Publications (1)

Publication Number	Publication Date
PT867178E true PT867178E (pt)	2002-04-29

Family

ID=7766768

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT98102355T PT867178E (pt)	1995-07-13	1996-07-10	Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
PT98102356T PT867184E (pt)	1995-07-13	1996-07-10	Utilizacao de tiagabina para o tratamento de desordens do sono
PT96925704T PT840601E (pt)	1995-07-13	1996-07-10	Thip para o tratamento de desordens do sono

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PT98102356T PT867184E (pt)	1995-07-13	1996-07-10	Utilizacao de tiagabina para o tratamento de desordens do sono
PT96925704T PT840601E (pt)	1995-07-13	1996-07-10	Thip para o tratamento de desordens do sono

Country Status (12)

Country	Link
US (1)	US5929065A (pt)
EP (3)	EP0867178B1 (pt)
JP (3)	JP3754705B2 (pt)
AT (3)	ATE207349T1 (pt)
AU (1)	AU723954B2 (pt)
CA (1)	CA2226582C (pt)
CL (1)	CL2003002785A1 (pt)
DE (4)	DE19525598C2 (pt)
DK (3)	DK0867184T3 (pt)
ES (3)	ES2166111T3 (pt)
PT (3)	PT867178E (pt)
WO (1)	WO1997002813A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5914333A (en) *	1996-07-31	1999-06-22	Novo Nordisk A/S	Treatment of psychotic disorders
IE970588A1 (en)	1997-08-01	2000-08-23	Elan Corp Plc	Controlled release pharmaceutical compositions containing tiagabine
AU8643698A (en) *	1997-08-01	1999-02-22	Elan Corporation, Plc	Controlled release pharmaceutical compositions containing tiagabine
EP1220658A1 (en) *	1999-09-28	2002-07-10	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
IL152770A0 (en) *	2000-06-26	2003-06-24	Warner Lambert Co	Gabapentin analogues for sleep disorders
CN1511026A (zh) *	2001-05-21	2004-07-07	H��¡�±��޹�˾	加波沙朵颗粒制剂
DK1641456T3 (da)	2003-06-25	2010-06-21	Lundbeck & Co As H	Gaboxadol til behandling af depression og andre affektive lidelser
AR045540A1 (es)	2003-09-05	2005-11-02	Lundbeck & Co As H	Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) *	2003-09-10	2007-02-08	Mckernan Ruth	Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050176680A1 (en)	2003-12-11	2005-08-11	Sepracor, Inc.	Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) *	2003-12-18	2005-06-23	H. Lundbeck A/S	Treatment of insomnia in human patients
TW200528098A (en) *	2003-12-18	2005-09-01	Lundbeck & Co As H	Treatment of insomnia in human patients
WO2005063248A1 (en) *	2003-12-22	2005-07-14	Sepracor Inc.	Modafinil combination therapy for improving sleep quality
CA2551637A1 (en) *	2003-12-24	2005-07-14	Sepracor Inc.	Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) *	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
WO2005079851A2 (en) *	2004-02-18	2005-09-01	Sepracor, Inc.	Dopamine-agonist combination therapy with sedatives for improving sleep quality
JP2007530604A (ja) *	2004-04-02	2007-11-01	ハー・ルンドベック・アクチエゼルスカベット	呼吸機能障害の治療
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
WO2006083682A2 (en)	2005-01-28	2006-08-10	H.Lundbeck A/S	Polymorphic forms of a gabaa agonist
JP5380930B2 (ja) *	2007-07-24	2014-01-08	大正製薬株式会社	睡眠改善剤
DK3151832T3 (da)	2014-06-06	2021-06-14	Ovid Therapeutics Inc	Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
AU2016236239B2 (en)	2015-03-24	2020-06-25	H. Lundbeck A/S	Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
IL256912B2 (en)	2015-07-17	2024-01-01	Ovid Therapeutics Inc	Methods of treating developmental disorders with gaboxadol
US9682069B2 (en)	2015-07-17	2017-06-20	Ovid Therapeutics Inc	Methods of treating Dravet syndrome
EP4233861A3 (en)	2016-08-11	2023-10-11	Ovid Therapeutics, Inc.	Compositions for treatment of essential tremor
US10071083B2 (en)	2017-02-03	2018-09-11	Ovid Therapeutics Inc	Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja)	2017-08-04	2020-10-08	オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	糖尿病および関連する状態の処置におけるガボキサドールの使用
MX2021003302A (es)	2018-09-20	2021-05-13	Ovid Therapeutics Inc	Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en)	2018-11-21	2021-09-21	Certego Therapeutics Inc.	Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3894028B1 (en)	2018-12-14	2024-07-31	Raimondo Fazio	Martial arts training device
EP3880201A4 (en)	2018-12-17	2022-07-27	Ovid Therapeutics Inc.	USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
EP4051272A4 (en)	2019-12-18	2023-01-04	Ovid Therapeutics Inc.	GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1P36 DELETION SYNDROME
MX2022014599A (es)	2020-05-20	2022-12-16	Certego Therapeutics Inc	Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
KR102773472B1 (ko) *	2021-05-21	2025-02-27	한국식품연구원	구릿대 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
US20240269206A1 (en) *	2021-08-11	2024-08-15	Psyched Wellness Ltd.	Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) *	1986-06-30	1988-11-22	University Of Florida	Method for eliciting anxiolysis
US5167228A (en) *	1987-06-26	1992-12-01	Brigham And Women's Hospital	Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) *	1990-05-07	1993-03-09	Alza Corporation	Dosage form for treating central nervous system disorders
US5185446A (en) *	1990-09-04	1993-02-09	Neurogen Corporation	Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) *	1991-04-02	1991-04-02	Novo Nordisk As	Krystalinsk stof og dets fremstilling
US6077839A (en) *	1992-03-19	2000-06-20	Allergan Sales, Inc.	Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

1995
- 1995-07-13 DE DE19525598A patent/DE19525598C2/de not_active Expired - Fee Related
1996
- 1996-03-01 US US08/609,461 patent/US5929065A/en not_active Expired - Lifetime
- 1996-07-10 DK DK98102356T patent/DK0867184T3/da active
- 1996-07-10 DE DE69616376T patent/DE69616376T2/de not_active Expired - Fee Related
- 1996-07-10 AT AT96925704T patent/ATE207349T1/de not_active IP Right Cessation
- 1996-07-10 PT PT98102355T patent/PT867178E/pt unknown
- 1996-07-10 AU AU66137/96A patent/AU723954B2/en not_active Ceased
- 1996-07-10 EP EP98102355A patent/EP0867178B1/en not_active Expired - Lifetime
- 1996-07-10 JP JP50463197A patent/JP3754705B2/ja not_active Expired - Fee Related
- 1996-07-10 PT PT98102356T patent/PT867184E/pt unknown
- 1996-07-10 WO PCT/EP1996/003018 patent/WO1997002813A1/en not_active Ceased
- 1996-07-10 EP EP96925704A patent/EP0840601B1/en not_active Expired - Lifetime
- 1996-07-10 ES ES98102356T patent/ES2166111T3/es not_active Expired - Lifetime
- 1996-07-10 AT AT98102355T patent/ATE207352T1/de not_active IP Right Cessation
- 1996-07-10 DE DE69616333T patent/DE69616333T2/de not_active Expired - Fee Related
- 1996-07-10 PT PT96925704T patent/PT840601E/pt unknown
- 1996-07-10 ES ES96925704T patent/ES2165990T3/es not_active Expired - Lifetime
- 1996-07-10 CA CA002226582A patent/CA2226582C/en not_active Expired - Fee Related
- 1996-07-10 DK DK96925704T patent/DK0840601T3/da active
- 1996-07-10 ES ES98102355T patent/ES2166110T3/es not_active Expired - Lifetime
- 1996-07-10 EP EP98102356A patent/EP0867184B1/en not_active Expired - Lifetime
- 1996-07-10 DK DK98102355T patent/DK0867178T3/da active
- 1996-07-10 AT AT98102356T patent/ATE207356T1/de not_active IP Right Cessation
- 1996-07-10 DE DE69616375T patent/DE69616375T2/de not_active Expired - Fee Related
2003
- 2003-12-30 CL CL200302785A patent/CL2003002785A1/es unknown
2004
- 2004-09-02 JP JP2004256133A patent/JP2005047925A/ja active Pending
2008
- 2008-08-25 JP JP2008215117A patent/JP2009057382A/ja active Pending

Also Published As

Publication number	Publication date
DK0867184T3 (da)	2002-02-18
EP0840601B1 (en)	2001-10-24
DE69616333T2 (de)	2002-07-04
AU6613796A (en)	1997-02-10
DE19525598A1 (de)	1997-01-16
WO1997002813A1 (en)	1997-01-30
ES2165990T3 (es)	2002-04-01
CA2226582A1 (en)	1997-01-30
EP0867178A1 (en)	1998-09-30
ATE207352T1 (de)	2001-11-15
JP2005047925A (ja)	2005-02-24
US5929065A (en)	1999-07-27
DK0867178T3 (da)	2002-02-18
JPH11509194A (ja)	1999-08-17
ES2166111T3 (es)	2002-04-01
DE69616376D1 (de)	2001-11-29
AU723954B2 (en)	2000-09-07
DK0840601T3 (da)	2002-02-18
DE69616333D1 (de)	2001-11-29
EP0840601A1 (en)	1998-05-13
ES2166110T3 (es)	2002-04-01
EP0867184A1 (en)	1998-09-30
DE69616375D1 (de)	2001-11-29
ATE207356T1 (de)	2001-11-15
DE69616376T2 (de)	2002-06-27
EP0867184B1 (en)	2001-10-24
DE69616375T2 (de)	2002-07-11
DE19525598C2 (de)	1997-09-25
ATE207349T1 (de)	2001-11-15
JP3754705B2 (ja)	2006-03-15
PT840601E (pt)	2002-04-29
CA2226582C (en)	2008-02-19
CL2003002785A1 (es)	2005-04-08
PT867184E (pt)	2002-04-29
EP0867178B1 (en)	2001-10-24
JP2009057382A (ja)	2009-03-19

Publication	Publication Date	Title
PT867178E (pt)	2002-04-29	Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
EP1091745A4 (en)	2003-08-27	TREATMENT OF HYPERPROLIFERATIVE DISEASES
IL114446A (en)	1999-08-17	Pharmaceutical preparation for pain management and process for its preparation
EA200101089A1 (ru)	2002-10-31	Новый способ лечения
ATE201598T1 (de)	2001-06-15	Verwendung von moxonidin zur behandlung neuropathischer schmerzen
BR0108261A (pt)	2003-03-05	Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
ES2173977T3 (es)	2002-11-01	Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
BR9508531A (pt)	1998-12-01	Emprego de selegilin para o tratamento de doença epilépticas
BR9708037A (pt)	1999-07-27	Método para o tratamento de abuso de substância
EP0904094A4 (en)	2002-06-26	TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN
DE69635282D1 (de)	2006-02-23	Behandlung der exzessiven aggressivität mit olanzapine
EE04951B1 (et)	2008-02-15	R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks
MX9700626A (es)	1997-05-31	USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
MX9704887A (es)	1998-06-30	Composiciones farmaceuticas para el tratamiento de trastornos depresivos.